canyon landscape

This is a prospective multi-center, placebo controlled, double-blind and randomized dose escalation study of 2 doses of ACI-24 versus Placebo over 24 months with a total of 21 visits.

All subjects will receive the study medication (ACI-24 or Placebo) 7 times via s.c. injection (12 months) and will be followed up for 12 months after the last dose with a final safety and efficacy assessment.

Status
Active, closed to enrollment
Location
Phoenix, Arizona
Total Participants
24
Primary Sponsor
AC Immune SA
Additional Sponsor(s)
National Institute on Aging (NIA)
Alzheimer's Disease Cooperative Study (ADCS)
LuMind Research Down Syndrome Foundation